The ASAP1 Knockout SK-HEP-1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human SK-HEP-1 cell line, engineered to disrupt the ASAP1 gene. This polyclonal format provides a heterogeneous pool of edited cells, enabling robust loss-of-function studies without single-cell clonal selection artifacts. The CRISPR/Cas9-mediated gene disruption in these cells offers a versatile model for investigating ASAP1-dependent biology in a liver sinusoidal endothelial-like context, supporting both mechanistic and translational research applications.
The parental SK-HEP-1 cell line originates from a human liver adenocarcinoma and displays endothelial characteristics, making it a widely accepted in vitro model for liver sinusoidal endothelial cells. These cells endogenously express markers associated with endothelial function and are extensively used to study angiogenesis, tumor-endothelial interactions, and the hepatic tumor microenvironment. Their unique hybrid phenotype bridges hepatic and vascular biology, providing a relevant platform for dissecting signaling pathways that govern cell migration and vascular remodeling.
ASAP1 encodes an Arf GTPase-activating protein that functions as a critical regulator of Arf6-dependent actin cytoskeleton dynamics and membrane trafficking. Upon activation by upstream signals??such as EGFR, SRC, and integrin engagement??ASAP1 localizes to focal adhesions where it interacts with scaffolding proteins including paxillin, cortactin, and FAK. These interactions facilitate ASAP1-mediated modulation of Arf6, Rac1, and RhoA, promoting actin filament reorganization, membrane ruffling, and enhanced cell motility. The ASAP1 signaling axis comprises core components such as Arf6, GEP100, ASAP1 itself, and the actin cytoskeleton, forming a node that transduces signals from receptor tyrosine kinases and adhesion receptors to cytoskeletal remodeling.
In the SK-HEP-1 background, ablation of ASAP1 provides a focused model to interrogate its contribution to endothelial-like cell migration, invasion, and angiogenic processes. Given the role of liver sinusoidal endothelial cells in hepatocellular carcinoma progression and metastasis, the ASAP1 knockout polyclonal population allows researchers to dissect how loss of this ArfGAP alters Arf6-driven cytoskeletal rearrangements in a hepato-vascular context. This system is particularly relevant for understanding the molecular underpinnings of tumor microenvironment remodeling and metastatic dissemination in liver cancers and other epithelial malignancies where ASAP1 is dysregulated.
This knockout model is suited for a wide range of functional assays, including wound healing and transwell migration/invasion assays to assess motility, immunofluorescence microscopy to visualize actin cytoskeletal changes, and western blotting to evaluate downstream effector activation. Arf6 activity assays and Rho GTPase activation assays can directly probe GTPase signaling, while co-immunoprecipitation experiments enable mapping of altered protein interactions such as between ASAP1 and paxillin or cortactin. These applications facilitate target validation for anti-metastatic therapies and mechanistic studies of Arf6-mediated signaling. For further details, researchers are encouraged to contact Ascent Research.
